T. T. Brown and R. B. Qaqish, Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review, AIDS, vol.20, pp.2165-2174, 2006.

V. A. Triant, T. T. Brown, H. Lee, and S. K. Grinspoon, Fracture prevalence among human immunodeficiency virus (HIV)-infected versus non-HIV-infected patients in a large U.S. healthcare system, J Clin Endocrinol Metab, vol.93, pp.3499-3504, 2008.

R. Gu?erri-fernandez, P. Vestergaard, and C. Carbonell, HIV Infection Is Strongly Associated With Hip Fracture Risk, Independently of Age, Gender, and Comorbidities:A Population-Based Cohort Study, J. Bone Miner. Res, vol.28, pp.1259-1263, 2013.

D. Prieto-alhambra, R. Gu?erri-fernández, D. Vries, and F. , HIV Infection and Its Association With an Excess Risk of Clinical Fractures: A Nationwide Case-Control Study, JAIDS, vol.66, pp.90-95, 2014.

J. A. Womack, J. L. Goulet, and C. Gibert, Increased risk of fragility fractures among HIV-infected compared to uninfected male veterans, PloS One, vol.6, p.17217, 2011.

B. Young, C. N. Dao, K. Buchacz, R. Baker, and J. T. Brooks, Increased rates of bone fracture among HIVinfected persons in the HIV Outpatient Study (HOPS) compared with the US general population, Clin Infect Dis, vol.52, pp.1061-1068, 2006.

A. Sharma, Q. Shi, and D. R. Hoover, increased fracture incidence in middle-aged HIV-infected and uninfected women: updated results from the Women's Interagency HIV Study, JAIDS, vol.70, pp.54-61, 2015.

B. Grund, G. Peng, and C. L. Gibert, Continous antiretroviral therapy decreases bone mineral density, AIDS, vol.23, pp.1519-1529, 2009.

A. B. Hansen, N. Obel, H. Nielsen, C. Pedersen, and J. Gerstoft, Bone mineral density changes in protease inhibitor-sparing vs. nucleoside reverse transcriptase inhibitor-sparing highly active antiretroviral therapy: data from randomized trial, HIV Med, vol.12, pp.157-165, 2011.

G. A. Mccomsey, D. Kitch, and E. S. Daar, Bone mineral density and fracture in antiretroviral-naïve persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy of ACTG A5202, J Infect Dis, vol.203, pp.1791-1801, 2011.

H. J. Stellbrink, C. Orkin, and J. R. Arribas, Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study, Clin Infect Dis, vol.51, pp.963-972, 2010.

C. Duvivier, S. Kolta, and L. Assoumou, Greater decrease in bone mineral density with protease inhibitor regimens compared with non nucleoside reverse transcriptase inhibitor regimens in HIV-1 infected naïve patients, AIDS, vol.23, pp.817-824, 2009.

E. Bonnet, J. B. Ruidavets, and A. Genoux, Early loss of bone mineral density is correlated with a gain of fat mass in patients starting a protease inhibitor containing regimen: the prospective Lipotrip study, BMC infection, vol.2013, p.293
URL : https://hal.archives-ouvertes.fr/inserm-00843065

E. W. Yu, B. J. Thomas, J. K. Brown, and J. S. Finkelstein, Simulated increases in body fat and errors in bone mineral density measurements by DXA and QCT, J Bone Miner Res, vol.27, pp.119-143, 2012.

A. Y. Liu, E. Vittinghoff, and D. E. Sellmeyer, Bone mineral density in HIV-negative men participating